SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Introgen Therapeutics
INGN 6.630-1.3%Jan 2 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: zeta1961 who wrote (74)6/9/2004 8:22:52 PM
From: Ian@SI of 802
 
Zeta,

1. RAGL = Regards and Good Luck.
2. If you haven't run across CTIC in your very early but potentially dramatic Pancreatic cancer treatments, look at their recent press releases.

In a Ph 1 for one of the products (PR released during the past week), several Pancreatic patients showed a response (I believe at least one was a complete response, but my memory sometimes plays nasty little tricks on me). I got the impression that they were probably going to target other cancers first, but this sounded rather striking to me given that it was only a Ph1, and that Pancreatic cancer just doesn't seem to be responsive to any current treatment.

Best wishes,
Ian
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News